AtriCure Stock News

AtriCure Inc. (ATRC) CEO Michael Carrel on Q4 2021 Results - Earnings Call Transcript

AtriCure press release (ATRC): Q4 Non-GAAP EPS of -$0.30 beats by $0.01.Revenue of $73.22M (+26.8% Y/Y) beats by $0.56M.

MASON, Ohio,--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. “We achieved several milestones in 2021 including the approval and launch of Hybrid Therapy™ for treatment of patients with long-standing persistent Afib, a result of our groundbreaking CONVERGE™ tri

AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage Bladder, Thyroid Cancer

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street analysts expect that AtriCure, Inc. (NASDAQ:ATRC) will report sales of $72.28 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for AtriCures earnings. The highest sales estimate is $74.00 million and the lowest is $71.10 million. AtriCure posted sales of $57.73 million during the same quarter last []

AtriCure, Inc. (NASDAQ:ATRC) insider Tonya Austin sold 1,528 shares of AtriCure stock in a transaction on Friday, December 10th. The stock was sold at an average price of $70.88, for a total transaction of $108,304.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Tonya Austin also []

Equities research analysts expect AtriCure, Inc. (NASDAQ:ATRC) to post $72.28 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCures earnings, with the highest sales estimate coming in at $74.00 million and the lowest estimate coming in at $71.10 million. AtriCure posted sales of $57.73 million in the []

Analysts expect that AtriCure, Inc. (NASDAQ:ATRC) will announce sales of $72.28 million for the current quarter, Zacks reports. Five analysts have provided estimates for AtriCures earnings, with estimates ranging from $71.10 million to $74.00 million. AtriCure reported sales of $57.73 million during the same quarter last year, which would suggest a positive year-over-year growth rate []

Parametric Portfolio Associates LLC lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 74.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,284 shares of the medical device companys stock after purchasing an additional 24,100 shares during the period. []